^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

    Excerpt:
    ...have documented EGFR mutation or EGFR gene amplification, regardless of demographic or clinical characteristics, who have had...
    Trial ID:
    NCT00729742
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

    Excerpt:
    ...Extent of inhibition of epidermal growth factor receptor (EGFR) and AKT phosphorylation by erlotinib hydrochloride`Toxicity`Frequency and proportion of patients with complete response, partial response, stable disease, and progressive disease`Comparison of ex vivo and in vivo effects of erlotinib hydrochloride`Proportion of patients with EGFR gene amplification and gene mutation with an ex vivo response and clinical response...
    Trial ID:
    NCT00673569
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

    Excerpt:
    Increased EGFR gene copy number was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001)...
    DOI:
    10.1093/annonc/mdq432